Experience

Julius Clinical

• Netherlands
• Pharmaceutical Manufacturing
• 100 - 200 Employee

• Project Compliance Manager

  • Feb 2023 - Present



iClusion

• Netherlands
• Hospitals and Health Care
• 1 - 100 Employee

• Manager Trial Centers - NL

  • Jan 2020 - Jan 2023



ICON plc

• Ireland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Clinical Research Associate

  • Oct 2019 - Dec 2019



Chiltern

• Pharmaceutical Manufacturing
• 400 - 500 Employee

• Clinical Research Associate

  • Sep 2018 - Sep 2019



Novartis Oncology

• Switzerland
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Clinical Research Associate

  • Dec 2015 - Aug 2018

  Monitor experience in the following disease areas; Cushing disease, Dumping syndrome, Acromegaly, Chronic myeloid leukemia, Breast cancer, Acute myeloid leukemia, Solid tumors, Melanoma and Bladder cancer. Good knowledge of clinical research regulatory requirements; i.e., Good Clinical Practice (GCP) and International Conference on Harmonization (ICH) guidelines. Experienced working with many different kind of vendor’s (such as bioclinica, cenduit, ert etc). Experienced in clinical monitoring and site management. Maintained timelines of data base locks of several high priority studies. Ability to manage time appropriately and ensure that detailed reports are turned in on time. Helped multiple trial centers during challenging times. Assisted colleagues who just started their CRA career. Show less



UMCG

• Netherlands
• Hospitals and Health Care
• 700 & Above Employee

• PhD student

  • Sep 2009 - Mar 2014

  My research project was part of a large multidisciplinary consortium (BMM, BioMedical Materials Program) which consisted of several companies and different academic partners. My role within this project was to evaluate and select candidate polymers in vitro and evaluate their biocompatibility in vivo. This evaluation and selection of the polymers was based on their in vitro cytotoxicity according to ISO guidelines. Secondly, the selected polymers were tested in a rat subcutaneous foreign body reaction model for their in vivo biocompatibility. Finally the best polymers were loaded with a drug and injected underneath the kidney capsule in a kidney damage model in rats. In this model we have shown that local drug delivery is possible, with increased drug related effects combined with reduced side effects. In the last 2 years of the project I took over many responsibilities such as reporting to BMM, organizing and participating in meetings with the other partners. “Microspheres for local drug delivery”, thesis defense (6 January 2016) Dept. Pathology and Medical Biology – Tissue generation and repair research group Show less



University of Groningen

• Netherlands
• Research Services
• 700 & Above Employee

• MSc

  • Sep 2001 - Aug 2009

  During my study I did 3 internships: Master research (January 2009 – June 2009) Rijksuniversiteit Groningen (RuG), Department of Medical Biology - University Medical Center Groningen (UMCG) Title: Hydrogels containing human recombinant gelatin for permanent skin filling In this project I studied six different candidate dermal fillers and evaluated there in vivo biocompatibility and degradation. In this project we have shown that during the degradation of the gel the cells involved in the foreign body response are able to deposit extracellular matrix in return, which provides permanent skin filling. Master research (September 2005 - March 2006) Rijksuniversiteit Groningen (RuG), Department of Tumor Immunology – University Medical Center Groningen (UMCG) Title: Specific killing of leukemic T-cells with a recombinant fusion protein restricted for CD7 In this project I studied the specific targeting of leukemic T-cells with a recombinant fusion protein restricted for CD-7, which is overexpressed by leukemic T-cells. Here, CD-7 was combined with an apoptotic ligand called FasL. We showed that in a mixture of healthy and leukemic blood cells, the fusion protein selectively induced apoptosis in the diseased blood cells. Master research (September 2004 – June 2005) Rijksuniversiteit Groningen (RuG), Department of Clinical Pharmacology Title: EPO rather than hemoglobin is responsible for cardiac protection during ischemia reperfusion injury In this project I studied the cardio protective effect of EPO during ischemia reperfusion in the heart. I learned how to induce a myocardial infarction in a rat and other operating techniques. The study showed that high levels of EPO during a myocardial infarction significantly reduce infarction size. Show less